Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Genetic Predisposition to Ocular Surface Disorders and Opportunities for Gene-Based Therapies Publisher Pubmed



Roshandel D1, 2 ; Semnani F3, 4 ; Rayati Damavandi A3, 4 ; Masoudi A5 ; Baradaranrafii A6, 7 ; Watson SL8 ; Morgan WH1, 2 ; Mclenachan S1, 2
Authors
Show Affiliations
Authors Affiliations
  1. 1. Lions Eye Institute, Perth, WA, Australia
  2. 2. Centre for Ophthalmology and Visual Science, The University of Western Australia, Perth, WA, Australia
  3. 3. School of Public Health, Tehran University of Medical Sciences (TUMS), Tehran, Iran
  4. 4. School of Medicine, Tehran University of Medical Sciences (TUMS), Tehran, Iran
  5. 5. Stein Eye Institute, David Geffen School of Medicine, University of California, Los Angeles, CA, United States
  6. 6. Department of Ophthalmology, Research Institute for Ophthalmology and Vision Science, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  7. 7. Department of Ophthalmology, Morsani College of Medicine, University of South Florida, Tampa, FL, United States
  8. 8. The University of Sydney, Save Sight Institute, Discipline of Ophthalmology, Sydney Medical School, Sydney, NSW, Australia

Source: Ocular Surface Published:2023


Abstract

The ocular surface, comprised of the corneal and conjunctival epithelium, innervation system, immune components, and tear-film apparatus, plays a key role in ocular integrity as well as comfort and vision. Gene defects may result in congenital ocular or systemic disorders with prominent ocular surface involvement. Examples include epithelial corneal dystrophies, aniridia, ectrodactyly-ectodermal dysplasia-clefting (EEC) syndrome, xeroderma pigmentosum (XP), and hereditary sensory and autonomic neuropathy. In addition, genetic factors may interact with environmental risk factors in the development of several multifactorial ocular surface disorders (OSDs) such as autoimmune disorders, allergies, neoplasms, and dry eye disease. Advanced gene-based technologies have already been introduced in disease modelling and proof-of-concept gene therapies for monogenic OSDs. For instance, patient-derived induced pluripotent stem cells have been used for modelling aniridia-associated keratopathy (AAK), XP, and EEC syndrome. Moreover, CRISPR/Cas9 genome editing has been used for disease modelling and/or gene therapy for AAK and Meesmann's epithelial corneal dystrophy. A better understanding of the role of genetic factors in OSDs may be helpful in designing personalized disease models and treatment approaches. Gene-based approaches in monogenic OSDs and genetic predisposition to multifactorial OSDs such as immune-mediated disorders and neoplasms with known or possible genetic risk factors has been seldom reviewed. In this narrative review, we discuss the role of genetic factors in monogenic and multifactorial OSDs and potential opportunities for gene therapy. © 2023 The Authors